Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Claudia C. Roskopf"'
Autor:
Todd A. Braciak, Claudia C. Roskopf, Sarah Wildenhain, Nadja C. Fenn, Christian B. Schiller, Ingo A. Schubert, Uwe Jacob, Annemarie Honegger, Christina Krupka, Marion Subklewe, Karsten Spiekermann, Karl-Peter Hopfner, Georg H. Fey, Michael Aigner, Stefan Krause, Andreas Mackensen, Fuat S. Oduncu
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of AML cells. Here we describe the development and key biological pro
Externí odkaz:
https://doaj.org/article/9c33b3300b544ab9bf536064eecde761
Autor:
Julia L. Zimmermann, Claudia C. Roskopf, Sylvia Cantzler, Jens Kirsch, Rico Unger, Hannes Weilemann, Maximilian Cantzler, Michael Linner, Martin Wunderl, Tim Maisch
Publikováno v:
Textbook of Good Clinical Practice in Cold Plasma Therapy ISBN: 9783030878566
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f458c81829eb40ffe4d2e49dc63e9811
https://doi.org/10.1007/978-3-030-87857-3_19
https://doi.org/10.1007/978-3-030-87857-3_19
Autor:
Ingo Schubert, Christina Krupka, Andreas Mackensen, Karsten Spiekermann, Annemarie Honegger, Sarah Wildenhain, Todd A. Braciak, Stefan W. Krause, Marion Subklewe, Nadja C. Fenn, Uwe Jacob, Christian B. Schiller, Georg H. Fey, Michael Aigner, Claudia C. Roskopf, Fuat Oduncu, Karl-Peter Hopfner
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
Oncoimmunology
Oncoimmunology
A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of AML cells. Here we describe the development and key biological pro
Autor:
Todd A. Braciak, Sebastian Kobold, Fuat Oduncu, Karl-Peter Hopfner, Georg H. Fey, Christian B. Schiller, Claudia C. Roskopf, Ingo Schubert
Publikováno v:
Oncotarget
ResearcherID
ResearcherID
Triplebody 19-3-19, an antibody-derived protein, carries three single chain fragment variable domains in tandem in a single polypeptide chain. 19-3-19 binds CD19-bearing lymphoid cells via its two distal domains and primary T cells via its CD3-target
Autor:
Karl-Peter Hopfner, Alexandra Schele, Ursula J.E. Seidel, Nadja C. Fenn, Annemarie Honegger, Christian B. Schiller, Todd A. Braciak, Sarah Wildenhain, Fuat Oduncu, Ingo Schubert, Kerstin Lämmermann, Peter Lang, Georg H. Fey, Claudia C. Roskopf, Uwe Jacob
Publikováno v:
Oncotarget
// Christian B. Schiller 1, * , Todd A. Braciak 2, * , Nadja C. Fenn 1, * , Ursula J. E. Seidel 3, * , Claudia C. Roskopf 2, * , Sarah Wildenhain 1, * , Annemarie Honegger * , Ingo A. Schubert 5 , Alexandra Schele 1 , Kerstin Lammermann 2 , Georg H.
Autor:
Claudia C. Roskopf, Farzad Sekhavati, Nadja C. Fenn, Georg H. Fey, Todd A. Braciak, Elisavet I. Chatzopoulou, Karl-Peter Hopfner, Joachim O. Rädler, Fuat Oduncu
Cancer therapy via redirected lysis mediated by antibodies and antibody-derived agents relies on the availability of substantial numbers of sufficiently active immune effector cells. To monitor antitumor responses before and during therapy, sensitive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aec674a3682ab1b80aa8f496af93820
https://opus4.kobv.de/opus4-fau/files/9226/Chatzopoulou_chip-based.pdf
https://opus4.kobv.de/opus4-fau/files/9226/Chatzopoulou_chip-based.pdf
Autor:
Nadja C. Fenn, Todd A. Braciak, Claudia C. Roskopf, Sebastian Kobold, Karl-Peter Hopfner, Georg H. Fey, Fuat Oduncu
Publikováno v:
Oncotarget
Simultaneous targeting of multiple tumor-associated antigens (TAAs) in cancer immunotherapy is presumed to enhance tumor cell selectivity and to reduce immune escape. The combination of B lymphoid marker CD19 and myeloid marker CD33 is exclusively pr
Autor:
Karl-Peter Hopfner, Nadja C. Fenn, Sarah Wildenhain, Christian B. Schiller, Uwe Jacob, Fuat Oduncu, Claudia C. Roskopf, Todd A. Braciak, Georg H. Fey
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts The design of antibody derivatives with higher tumour cell selectivity is hoped to improve cancer immunotherapy and to decrease side effects. One promising molecular format that we have developed is the triple body. A triple body al
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 5, p e0156268 (2016)
PLoS ONE, Vol 11, Iss 5, p e0156268 (2016)
In vitro cell-based models of lung cancer are frequently employed to study invasion and the mechanisms behind metastasis. However, these models often study only one cell type with two-dimensional (2D) monolayer cell cultures, which do not accurately
Autor:
Todd A. Braciak, Claudia C. Roskopf, Sarah Wildenhain, Georg H. Fey, Uwe Jacob, Fuat Oduncu, Ingo Schubert, Karl-Peter Hopfner
Publikováno v:
Journal of Translational Medicine
Background The capacity of patient’s Natural Killer cells (NKs) to be activated for cytolysis is an important prerequisite for the success of antibody-derived agents such as single-chain triplebodies (triplebodies) in cancer therapy. NKs recovered